Suppr超能文献

Smith-Lemli-Opitz 综合征患者的生物标志物与临床严重程度的关系。

Relation between biomarkers and clinical severity in patients with Smith-Lemli-Opitz syndrome.

机构信息

Department of Laboratory Medicine, Medical and Health Science Center, University of Debrecen, 98 Nagyerdei krt., Debrecen 4032, Hungary.

出版信息

Eur J Pediatr. 2013 May;172(5):623-30. doi: 10.1007/s00431-012-1925-z. Epub 2013 Jan 15.

Abstract

UNLABELLED

Smith-Lemli-Opitz syndrome (SLOS), a multiple congenital anomaly with severe mental retardation, is caused by decreased activity of 7-dehydrocholesterol reductase. Fifteen Hungarian patients were diagnosed with SLOS on the basis of clinical symptoms, serum cholesterol, 7-dehydrocholesterol, and molecular genetic testing. Their age at the time of diagnosis in mild SLOS (n = 4, clinical score <20) was 0.5-18 years, cholesterol was 2.37 ± 0.8 mmol/L, and 7DHC was 0.38 ± 0.14 mmol/L. In the group of typical SLOS (n = 7, score 20-50), the diagnosis was set up earlier (age of 0.1-7 years); t-cholesterol was 1.47 ± 0.7 mmol/L, and 7DHC was 0.53 ± 0.20 mmol/L. Patients with severe SLOS (n = 4, clinical score > 50) died as newborns and had the lowest t-cholesterol (0.66 ± 0.27 mmol/L), and 7DHC was 0.47 ± 0.14 mmol/L. Correlation coefficient with clinical severity was 0.74 for initial t-cholesterol and 0.669 for Cho/7DHC. Statistically significant difference was between the initial t-cholesterol of mild and severe SLOS (p = 0.01), and between the Cho/7DHC ratios of groups (p = 0.004). In severe SLOS, the percentage of α-lipoprotein was significantly lower than in typical (p = 0.003) and mild SLOS (p = 0.004). Although serum albumin, total bilirubin, and hemostasis parameters remained in the reference range during cholesterol supplementation (n = 10) combined with statin therapy (n = 9), increase of aspartate aminotransferase and alanine aminotransferase in 50 % of the patients probably refers to a reversible alteration of liver function; therefore, statin therapy was suspended.

CONCLUSION

life expectancy is fundamentally determined by the initial t-cholesterol, but dehydrocholesterol and α-lipoprotein have prognostic value. Accumulation of hepatotoxic DHC may inhibit the synthesis of α-lipoproteins, decreasing the reverse cholesterol transport. During statin therapy, we suggest monitoring of lipid parameters and liver function.

摘要

未加标签

Smith-Lemli-Opitz 综合征 (SLOS) 是一种多种先天畸形伴严重智力迟钝的疾病,由 7-脱氢胆固醇还原酶活性降低引起。15 名匈牙利患者基于临床症状、血清胆固醇、7-脱氢胆固醇和分子遗传学检测被诊断为 SLOS。在轻度 SLOS 患者(n = 4,临床评分 <20)中,确诊时的年龄为 0.5-18 岁,胆固醇为 2.37 ± 0.8 mmol/L,7DHC 为 0.38 ± 0.14 mmol/L。在典型 SLOS 组(n = 7,评分 20-50)中,诊断更早(0.1-7 岁);总胆固醇为 1.47 ± 0.7 mmol/L,7DHC 为 0.53 ± 0.20 mmol/L。严重 SLOS 患者(n = 4,临床评分 > 50)在新生儿期死亡,总胆固醇最低(0.66 ± 0.27 mmol/L),7DHC 为 0.47 ± 0.14 mmol/L。与临床严重程度的相关系数为初始总胆固醇为 0.74,Cho/7DHC 为 0.669。轻度和重度 SLOS 之间初始总胆固醇有统计学显著差异(p = 0.01),各组之间 Cho/7DHC 比值也有统计学显著差异(p = 0.004)。在严重 SLOS 中,α-脂蛋白的百分比明显低于典型 SLOS(p = 0.003)和轻度 SLOS(p = 0.004)。尽管在胆固醇补充(n = 10)联合他汀类药物治疗(n = 9)期间,血清白蛋白、总胆红素和止血参数仍在参考范围内,但 50%的患者天冬氨酸氨基转移酶和丙氨酸氨基转移酶升高可能提示肝功能可逆性改变;因此,停止了他汀类药物治疗。

结论

预期寿命主要由初始总胆固醇决定,但脱氢胆固醇和α-脂蛋白具有预后价值。肝毒性 DHC 的积累可能抑制α-脂蛋白的合成,减少胆固醇逆转运。在他汀类药物治疗期间,我们建议监测血脂参数和肝功能。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验